Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,589

Longevity Therapeutics Summit

On January 29–31, 2019, the Longevity Therapeutics Summit is happening at the Argonaut Hotel in San Francisco, California. The conference is a great networking opportunity with some leading names in aging research giving talks during the event.

This will be a two-day conference plus a pre-conference workshop hosted by our good friend Kelsey Moody from Ichor Therapeutics. During the workshop, Kelsey will be giving his personal insights into launching and developing a successful biotech company, particularly the challenges faced in the field of rejuvenation biotechnology. This is sure to be a highly informative workshop and well worth your time, especially if you are interested in launching your own company in this field, but even if you are not, it may still prove interesting to learn about this challenging industry.

This conference aims at bringing together leading figures in biology, biotechnology, omics, investment, and other fields in order to discuss how to further accelerate progress in aging research so that the time between basic research and clinical use is as short as possible.

Four Blind People Go Home With New Bionic Eyes

Bionic Vision Technologies, a firm based in Australia, has announced that its bionic eye system has been used to restore a “sense of sight” to four completely blind people suffering from retinitis pigmentosa. The findings from the study, which was performed at Royal Victorian Eye and Ear Hospital in Melbourne, were presented at the Royal Australian and New Zealand College of Ophthalmologists Scientific meeting.

Unlike previous studies of the technology that were limited to in-lab use, the four patients were able to use the system in their everyday environments.

This Startup Is Helping Build China’s Panopticon

The company will have to wrestle more seriously with ethical questions as it expands into new industries and countries. These include Japan, where it’s making road-tracking software to help steer driverless Hondas, and the U.S., where its New Jersey health lab is developing cancer detection software. It’s also working to bring interactive games to livestreamers in Southeast Asia, teaming up with the popular app Bigo.

SenseTime, the world’s most valuable AI startup, aims to bring its smarter-cameras-everywhere model, well, everywhere.

Brain-Destroying Prions Also Spread Through Victims’ Eyes

One of the strangest things that can sicken us—a rogue misfolded protein that destroys the brain, known as a prion—is even scarier than we knew. Researchers were able to find the prions responsible for sporadic Creutzfeldt-Jakob disease (sCJD), the most common prion disease in people, seeded everywhere in the eyes of 11 patients affected by it.

The findings are the latest to suggest that these universally fatal, if rare, diseases can be spread through the eyes. But they also indicate that our eyes might be someday be used to spot these cases with less hassle than current testing methods.

A time to fast

! A new review on the positive effects on lifespan and health of fasting and calorie restriction.

Nutrient composition and caloric intake have traditionally been used to devise optimized diets for various phases of life. Adjustment of meal size and frequency have emerged as powerful tools to ameliorate and postpone the onset of disease and delay aging, whereas periods of fasting, with or without reduced energy intake, can have profound health benefits. The underlying physiological processes involve periodic shifts of metabolic fuel sources, promotion of repair mechanisms, and the optimization of energy utilization for cellular and organismal health. Future research endeavors should be directed to the integration of a balanced nutritious diet with controlled meal size and patterns and periods of fasting to develop better strategies to prevent, postpone, and treat the socioeconomical burden of chronic diseases associated with aging.

The worldwide increase in life expectancy has not been paralleled by an equivalent increase in healthy aging. Developed and developing countries are facing social and economic challenges caused by disproportional increases in their elderly populations and the accompanying burden of chronic diseases. Geriatricians and gerontologists have contributed greatly to our understanding of the consequences and processes that underlie aging from clinical, social, mental, physical, and biological perspectives. The primary goal of aging research is to improve the health of older persons and to design and test interventions that may prevent or delay age-related diseases. Besides socioeconomic status, energy, environmental quality, and genetics are the most powerful determinants of health and longevity. Although environmental quality and genetics are not under our direct control, energy intake is.

Eurosymposium on Healthy Ageing – Sven Butlerijs

At the Eurosymposium on Healthy Ageing, we had the opportunity to interview Sven Butlerijs of the Healthy Life Extension Society (HEALES). Some of our regular readers may recall seeing Sven join us for some of the monthly episodes of the Journal Club and he is an active figure in the rejuvenation biotechnology field.

During the interview with Nicola Bagalà, Sven discusses the extracellular matrix, its role in human biomechanics, what happens when it ages and stiffens, the role of cross-linking in collagen, and the possibility of interventions.

Inhibiting USP13 Might Prove Effective Against Parkinson’s Disease

Researchers at Georgetown University Medical Center discovered that the protease USP13 (ubiquitin-specific peptidase 13) plays a role in the accumulation of toxic alpha-synuclein aggregates that characterize Parkinson’s disease [1].

Abstract

Ubiquitin specific proteases (USPs) are de-ubiquitinases that control the protein ubiquitination cycle. The role of de-ubiquitinases is poorly understood in neurodegenerative diseases. We found that USP13 is overexpressed in the post-mortem Parkinson’s disease (PD) brain. We investigated whether changes in USP13 levels can affect two molecules, parkin and alpha-synuclein, that are implicated in PD pathogenesis. Parkin is an E3 ubiquitin ligase that is regulated by ubiquitination and targets certain proteins for degradation, and alpha-synuclein may be ubiquitinated and recycled in the normal brain. We found that USP13 independently regulates parkin and alpha-synuclein ubiquitination in models of alpha-synucleinopathies. USP13 shRNA knockdown increases alpha-synuclein ubiquitination and clearance in a parkin-independent manner.